Novartis AG v Pharmacor Pty Limited

Link copied
Case Copied 24 min read

FEDERAL COURT OF AUSTRALIA

Novartis AG v Pharmacor Pty Limited [2023] FCA 804   

File number: NSD 506 of 2023
Judgment of: YATES J
Date of judgment: 14 July 2023
Catchwords: PRACTICE AND PROCEDURE – patents – where in the principal proceeding the respondent alleges that the patent in suit does not disclose the best method of performing the invention – discovery – where applicants oppose the respondent’s proposed discovery category  
Legislation:

Patents Act 1990 (Cth) ss 29, 40

Federal Court Rules 2011 (Cth) Sch 1

Cases cited: Sandvik Intellectual Property AB v Quarry Mining & Construction Equipment Pty Ltd [2017] FCAFC 138; 348 ALR 156
Division: General Division
Registry: New South Wales
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 62
Date of hearing: 13 July 2023
Counsel for the Applicants: Mr T Cordiner KC and Mr B Mee
Solicitor for the Applicants: Clayton Utz
Counsel for the Respondent: Mr D Larish
Solicitor for the Respondent: Ashurst Australia

ORDERS

NSD 506 of 2023
BETWEEN:

NOVARTIS AG

First Applicant

NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED (ACN 004 244 162)

Second Applicant

AND:

PHARMACOR PTY LIMITED (ACN 004 244 162)

Respondent

ORDER MADE BY:

YATES J

DATE OF ORDER:

14 JULY 2023

THE COURT ORDERS THAT:

Discovery

1.By 4.00 pm on 17 August 2023, the applicants give discovery (by way of a reasonable search in accordance with r 20.14(3) of the Federal Court Rules 2011 (Cth) (the Rules)) and inspection of documents within the category set out in the Annexure to these orders (excluding any duplicates of any documents) by:

(a)filing and serving a verified list of documents in accordance with r 20.17 of the Rules; and

(b)producing to the respondent's solicitors electronic copies of the documents within Part 1 of that verified list of documents.

2.When providing inspection of the documents discovered in accordance with Order 1, the applicants may exclude any document in respect of which a claim of privilege is made over the whole document, and may redact any part of a document that contains a communication with respect to which a claim of privilege is made.

3.The costs of an incidental to the interlocutory application filed on 7 July 2023 be reserved.

Separate Question

4.By 4.00 pm on 19 July 2023, the applicants file and serve any affidavit evidence in support of the interlocutory application filed by the applicants dated 11 July 2023 (Separate Question Application).

5.By 4.00 pm on 26 July 2023, the respondent file and serve any affidavit evidence in answer to the Separate Question Application.

6.By 4.00 pm on 1 August 2023, the applicants file and serve:

(a)any affidavit evidence in reply on the Separate Question Application; and

(b)submissions on the Separate Question Application, limited to 5 pages.

7.By 4.00 pm on 4 August 2023, the respondent file and serve submissions on the Separate Question Application, limited to 5 pages.

8.The matter be listed for hearing of the Separate Question Application at 10.15 am on 11 August…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Novartis AG v Pharmacor Pty Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2023] FCA 804
Decision Date

CaseChat Overview and Summary

The matter in question was between Novartis AG and Pharmacor Pty Limited, proceeding in the Federal Court of Australia. The dispute concerned an alleged infringement of a patent held by Novartis, which relates to a pharmaceutical composition comprising valsartan, a neutral endopeptidase inhibitor, and a pharmaceutically acceptable carrier. The core legal issues revolved around whether the patent disclosed the best method of performing the invention, and the scope of the patent as it pertains to the specific pharmaceutical composition in question.

The court was tasked with resolving the scope of discovery in the case, specifically focusing on documents that recorded or evidenced the description and evaluation of the pharmaceutical composition in question. The court found that the discovery sought by Pharmacor was within the scope of the patent dispute and was relevant to the issues at hand. The court determined that Novartis was required to conduct a reasonable search and produce documents within the specified category, excluding any duplicates and allowing for the exclusion or redaction of privileged documents. The court reserved the issue of costs incidental to the interlocutory application for later determination.

The court issued detailed orders for the discovery process, including deadlines for the production of a verified list of documents and electronic copies, as well as timelines for the exchange of affidavit evidence and submissions on the separate question application. The court also set deadlines for the filing of affidavit evidence in chief and in reply, and established a schedule for a joint expert conclave to prepare a joint expert report on the issue of inventive step. The orders aimed to ensure that the proceedings were managed efficiently and that all relevant evidence was properly disclosed and evaluated.

Orders

Orders of the court

Discovery

1. By 4.00 pm on 17 August 2023, the applicants give discovery (by way of a reasonable search in accordance with r 20.14(3) of the Federal Court Rules 2011 (Cth) (the Rules)) and inspection of documents within the category set out in the Annexure to these orders (excluding any duplicates of any documents) by:

(a) filing and serving a verified list of documents in accordance with r 20.17 of the Rules; and

(b) producing to the respondent's solicitors electronic copies of the documents within Part 1 of that verified list of documents.

2. When providing inspection of the documents discovered in accordance with Order 1, the applicants may exclude any document in respect of which a claim of privilege is made over the whole document, and may redact any part of a document that contains a communication with respect to which a claim of privilege is made.

3. The costs of an incidental to the interlocutory application filed on 7 July 2023 be reserved.

Separate Question

4. By 4.00 pm on 19 July 2023, the applicants file and serve any affidavit evidence in support of the interlocutory application filed by the applicants dated 11 July 2023 (Separate Question Application).

5. By 4.00 pm on 26 July 2023, the respondent file and serve any affidavit evidence in answer to the Separate Question Application.

6. By 4.00 pm on 1 August 2023, the applicants file and serve:

(a) any affidavit evidence in reply on the Separate Question Application; and

(b) submissions on the Separate Question Application, limited to 5 pages.

7. By 4.00 pm on 4 August 2023, the respondent file and serve submissions on the Separate Question Application, limited to 5 pages.

8. The matter be listed for hearing of the Separate Question Application at 10.15 am on 11 August 2023, with an estimate of one hour.

Affidavit Evidence

9. By 21 August 2023 the applicants file and serve their affidavit evidence in chief on their infringement claims.

10. By 21 September 2023, the respondent file and serve its affidavit evidence in chief on its invalidity claims.

11. By 21 November 2023 the respondent file and serve its affidavit evidence in answer on the infringement claims.

12. By 21 December 2023, the applicants file and serve their affidavit evidence in answer on the invalidity claims.

13. By 9 February 2024, the parties file and serve any affidavit evidence in reply on their respective claims.

14. The parties provide a copy of the Draft Standard Instructions to Expert Witnesses in Patent Litigation dated 2 June 2023 (which was provided by the Court to the parties on 6 July 2023) to any expert witness the party proposes to file affidavit evidence from on the question of inventive step (obviousness) at the time of, or as soon as practicable after, retaining the expert.

Joint Expert Report

15. On or before 16 February 2024, the parties:

(a) confer regarding the parties' expert witnesses who shall participate in a joint expert conclave and prepare a joint expert report, and the preparation of a protocol which addresses the matters referred to in sections C and E of the draft document titled Practice Note: Joint Expert Reports dated 2 June 2023 (which was provided by the Court to the parties on 6 July 2023) (Protocol); and

(b) provide an agreed list of conclave participants, together with an agreed Protocol, to the Associate to Justice Yates or, in the event of disagreement, a marked-up copy of the list of conclave participants and/or Protocol indicating the areas of disagreement.

16. On the date that the list of conclave participants and the Protocol are finalised in accordance with Order 15 above, the parties provide a copy of the Protocol to the parties' conclave participants (as specified).

17. From 1 to 15 March 2024, the parties’ expert witnesses (as specified) participate in a conclave, to be conducted in accordance with Part 7 of the Expert Evidence Practice Note (GPN-EXPT) and section E of the draft document referred to in Order 15(a).

18. On or before 15 March 2024, the conclave participants produce a joint expert report that complies with section E of the draft document referred to in Order 15(a).

19. The matter be listed for a pre-trial case management hearing, and for the determination of any disagreement on the matters in Order 15(b) above, on 19 February 2024 at 9.30 am.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Annexure

Discovery category

The following terms have the following meanings:

(a) Date of Filing means 16 January 2003.

(b) Document has the meaning set out in the Dictionary in Schedule 1 of the Federal Court Rules 2011 (Cth).

(c) NEP inhibitor means a neutral endopeptidase inhibitor.

(d) Novartis means Novartis AG, Novartis Pharmaceuticals Australia Pty Limited and related companies of either of them (separately, or together) and whether alone or together with any contractors, consultants or other third parties acting on their behalf.

1. All Documents created during the period from 16 January 1998 to the Date of Filing recording or evidencing the description and/or evaluation of any pharmaceutical composition and/or method of preparing any pharmaceutical composition comprising:

(a) valsartan (or a pharmaceutically acceptable salt thereof); and

(b) an NEP inhibitor (or a pharmaceutically acceptable salt thereof); and

(c) a pharmaceutically acceptable carrier,

in which the NEP inhibitor is sacubitril or sacubitrilat, and in which the valsartan (or a pharmaceutically acceptable salt thereof) and the NEP inhibitor (or a pharmaceutically acceptable salt thereof) are associated by non-covalent bonds.

Background

Background to the litigation

Novartis AG, a pharmaceutical company, filed a patent infringement lawsuit against Pharmacor Pty Limited, another pharmaceutical company, in the Federal Court of Australia. Novartis claims that Pharmacor has infringed a patent related to a pharmaceutical composition and method involving valsartan, a neutral endopeptidase inhibitor, and a pharmaceutically acceptable carrier. The patent in question was filed on 16 January 2003. The dispute arose due to Pharmacor's alleged infringement of this patent by producing and distributing a pharmaceutical composition that Novartis asserts falls within the scope of their patented invention. The case involves technical details regarding the composition and method of preparing the pharmaceutical product, as well as the nature of the bonds between the components.

This matter is an interlocutory application related to discovery and inspection of documents in the context of a broader patent infringement lawsuit. The case has not yet proceeded to a final hearing on the merits of the infringement or validity claims. Prior to this application, the court issued orders regarding the filing and service of affidavit evidence, as well as a pre-trial case management hearing to discuss the preparation of a joint expert report. The current application involves orders for discovery and inspection of specific documents related to the pharmaceutical composition and method at issue in the case.

Decision

Reasons for decision

Issues
1. Whether the respondent is entitled to discovery and inspection of the specified documents from the applicants.
2. Whether the applicants have any grounds to oppose the respondent's proposed discovery category.
3. The timing and scope of the discovery and inspection of documents, including any claims of privilege or redactions.
4. The costs of the interlocutory application filed on 7 July 2023.

Held
1. The respondent is entitled to discovery and inspection of the specified documents from the applicants.
2. The applicants do not have any grounds to oppose the respondent's proposed discovery category.
3. The timing and scope of the discovery and inspection of documents are set out in the orders, with specific provisions for privilege claims and redactions.
4. The costs of the interlocutory application filed on 7 July 2023 are reserved.

Ratio Decidendi

Legal Principle Established

The court considered the principles governing discovery and inspection in the Federal Court of Australia, as outlined in the Federal Court Rules 2011 (Cth). The court noted that the discovery and inspection of documents are integral to the fair administration of justice, especially in patent disputes where the validity and infringement of patents are at issue. The court examined the scope of the discovery category proposed by the respondent and concluded that it was reasonable and necessary for the respondent to assess the patent's validity. The court further held that the applicants' opposition to the discovery category was not substantiated and did not provide sufficient grounds to limit the respondent's access to the documents. The court emphasised that privilege claims and redactions could be considered in the context of providing inspection, but the primary focus was on ensuring the respondent had adequate information to prepare their case. Regarding the timing and scope of discovery, the court set out detailed timelines and procedures to manage the discovery process efficiently, ensuring that the interests of both parties were balanced. The court reserved the costs of the interlocutory application, indicating that a separate determination would be made on the costs associated with this part of the proceedings.

The ratio decidendi of this decision is that in patent litigation, the court will support broad discovery and inspection rights to facilitate the thorough examination of patents, provided that the scope and timing of such discovery are reasonable and balanced against the need to protect legitimate claims of privilege and confidentiality. The court will not entertain unjustified opposition to the scope of discovery unless compelling grounds are presented.